

## Phone

Oncology Oral Enrollment Form	□ New to Therapy
e: 877-437-9012 Fax: 877-309-0687	☐ Current Therapy

Patient Information	Prescriber Information						
Patient Name:  Date of Birth: Gender: SS#	Practice/Organization Name: Prescriber Name: Contact Person: Address: City: State: Office Phone#: DEA# NPI# License#: NPI# License#: Medicaid UPIN#: Physician Specialty: Date Shipment Needed: Ship to: Patient Prescriber Shipment Address: City: State: Sta						
Diagnosis and Clinical Information							
Diagnosis (ICD-10): Description: Date of Diagnosis or Years with Disease: Cancer Stage: \Boxedown Stage I \Boxedown Stage II \Boxedown Stage III \Boxedown Stage IV \Boxedown Other: Has the patient been treated previously for this condition: \Boxedown No \Boxedown Yes  Previous Medications: Is the patient currently on other chemotherapeutic medications: \Boxedown No \Boxedown Yes							
Concurrent Medications:  Patient Height:  Patient S Allergies:  First Cycle Start Date:  Current Medications:  Comorbidities:  Shipment to Patient  Yes  No Shipment to Provider: Yes  No Sh	Latex allergy: □Yes □No Cycle Length:						

Privacy & Confidentiality of Information Notice: This communication may contain non-public, confidential, or legally privileged information intended for the sole use of the designated recipient(s). If you are not the intended recipient, or have received this communication in error, please notify the sender immediately by reply email or by telephone at the number stated above and delete all copies of this communication, including any attachments, without reading them or saving them to disk. If you are the intended recipient, you must secure the contents of this communication in accordance with all applicable state or federal requirements related to the privacy and confidentiality of information, including the HIPAA Privacy guidelines.



## Oral Oncology Enrollment Form Phone: 877-437-9012 Fax: 877-309-0687

	New	to	Гherapy
]	Curre	ent	Therapy

Patient Name: Patient Date of Birth:							
Prescriber Name:					Date:		
Prescriber Address:							
Medication:							
☐ Afinitor (everolimus)		☐ Ibrance (palbociclib)	☐ Mektovi (binimetinib)		☐Sprycel (dasatinib)	☐Tykerb (lapatinib)	
☐ Afinitor Disperz (eve	rolimus)	☐ Idhifa (enasidenib)	□Nexavar (sorafenib)		☐Sutent (sunitinib malate)	□Votrient (pazopanib)	
☐Alecensa (alectinib)		☐ Inlyta (axitinib)	☐ Odomzo (sonidegib)		☐Tabrecta (capmatinib)	□Xalkori (crizotinib)	
☐Bosulif (bosutinib)		☐ Inrebic (fedratinib)	☐Onureg (azacitidine)		☐Tafinlar (dabrafinib)	□Xeloda (capecitabine)	
☐Braftovi (encorafenib)		☐ Iressa (gefitinib)	☐Piqray (alpelisib)		☐Talzenna (talazoparib)	☐Yonsa (abiraterone acetate)	
□Cytoxan (cyclophosp	hamide	e)   Kisqali (ribociclib)	□Purixan (mercaptopurine)		☐Tarceva (erlotinib)	□Zolinza (vorinostat)	
□Erivedge (vismodegib)		☐ Lenvima (Lenvatinib)	□Rozlytrek (entrectinib)		☐Targretin (bexarotene)	□Zykadia (ceritinib)	
☐Gleevec (imatinib mesylate)		□Lorbrena (lorlatinib)	□Rydapt (midostaurin)		☐Tasigna (nilotinib)	□Zytiga (abiraterone)	
☐Gleostine (lomustine)		☐ Mekinist (trametinib)	□Scemblix (asciminib)		☐Temodar (temozolomide)	☐ Other:	
Drug	Dose	Directions/Frequency	Hold for Labs (Y/N)	Quantity Prescribed	Refills Allowed	□Anastrozole □Letrozole □Dexamethasone □Prednisone	
						□Exemastane □Zoladex	
						□Fulvestrant	
Pre-Chemo Orders/Special Instructions:  Post-Chemo Orders/Special Instructions:							
X Date: Physician Signature (no stamps)							
		If Brand required "Dispense as Written" must be hand written in box					

Privacy & Confidentiality of Information Notice: This communication may contain non-public, confidential, or legally privileged information intended for the sole use of the designated recipient(s). If you are not the intended recipient, or have received this communication in error, please notify the sender immediately by reply email or by telephone at the number stated above and delete all copies of this communication, including any attachments, without reading them or saving them to disk. If you are the intended recipient, you must secure the contents of this communication in accordance with all applicable state or federal requirements related to the privacy and confidentiality of information, including the HIPAA Privacy guidelines.